Acquired Bleeding Disorder, Cardiac Surgery Requiring Cardiopulmonary Bypass, Healthy
Conditions
Brief summary
This trial is conducted in Japan. The aim of this trial is to investigate the safety profile of recombinant factor XIII (rFXIII) assessed by the occurrence of adverse events in healthy Japanese subjects. In addition pharmacokinetic parameters will be investigated.
Interventions
DRUGcatridecacog
Single rFXIII dose (12 IU/kg). Administered via slow intravenous (i.v.) push at a rate not exceeding two mL per minute.
DRUGplacebo
Single rFXIII placebo dose (12 IU/kg). Administered via slow intravenous (i.v.) push at a rate not exceeding two mL per minute.
Sponsors
Novo Nordisk A/S
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
MALE
Age
20 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* Good general health based on assessment of medical history, physical examination, ECG (electrocardiogram) and clinical laboratory data at screening, as judged by the physician * Body mass index (BMI) between 18.0-27.0 kg/m2 (both inclusive)
Exclusion criteria
* The receipt of any investigational products for coagulation factor protein within 6 months prior to trial start (screening) * Known or suspected allergy to yeast * Known bleeding or hematologic disorder * Significant history of alcoholism or drug/chemical abuse as judged by the physician or positive result in the alcohol breath test/screen of drugs at the trial start (screening) * Smoking more than 10 cigarettes/day or equivalent * Not able or willing to refrain from smoking whenever required for the trial procedures * Habitual excessive consumption of methylxanthine-containing beverages and foods (coffee, tea, soft drinks such as cola, chocolate) as judged by the physician * Excessive consumption of a diet deviating from a normal diet as judged by the physician * Strenuous exercise as judged by the physician within 4 days prior to trial start (screening) * Surgery or trauma with significant blood loss (500 mL or more blood) within 3 months prior to trial start (screening) * Males who are sexually active and not surgically sterilised, who or whose partner are not using adequate contraceptive methods. Adequate contraceptive measures include that the subject uses a condom during intercourse or that the partner practices adequate conception (sterilisation, hormonal intrauterine devices and oral contraceptives).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Occurrence of serious adverse events | from first trial related activity (visit 1) and up to 28 days (visit 8) after dosing |
| Occurrence of non-serious adverse events | from first trial related activity (visit 1) and up to 28 days (visit 8) after dosing |
Secondary
| Measure | Time frame |
|---|---|
| AUC (area under the curve) from time zero to 28 days | at day 28 |
Countries
Japan
Outcome results
None listed